ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Rhea-AI Summary

ENDRA Life Sciences Inc. (NDRA) will report financial results for Q4 and full year 2023 on March 28, 2024. The company will host a conference call to discuss results, corporate updates, and answer questions.

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the start of the call. Those unable to pre-register may participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465 (International). A webcast of the call can also be accessed at ENDRA’s Investor Relations page and here.

A telephone replay will be available until April 4, 2024 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 8041087. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50^th the cost and at the point of patient care. TAEUS^® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240321544727/en/

Company:

Irina Pestrikova

Senior Director, Finance

investors@endrainc.com

www.endrainc.com

Investor Relations:

Yvonne Briggs

LHA Investor Relations

(310) 691-7100

ybriggs@lhai.com

Source: ENDRA Life Sciences Inc.

FAQ

When will ENDRA Life Sciences Inc. report financial results for Q4 and full year 2023?

ENDRA Life Sciences Inc. will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024.

What is the ticker symbol for ENDRA Life Sciences Inc.?

The ticker symbol for ENDRA Life Sciences Inc. is NDRA.

How can participants access the conference call for ENDRA Life Sciences Inc. financial results?

Participants can access the conference call by pre-registering using the provided link or by dialing (844) 868-8846 (U.S.) or (412) 317-5465 (International).

How long will the telephone replay be available for ENDRA Life Sciences Inc. conference call?

The telephone replay will be available until April 4, 2024 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 8041087.

Where can participants access the webcast replay of ENDRA Life Sciences Inc. conference call?

The webcast replay will be available beginning approximately one hour after the completion of the live conference call on ENDRA's Investor Relations page.